Filing Details
- Accession Number:
- 0000950170-24-003984
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-11 17:11:49
- Reporting Period:
- 2024-01-09
- Accepted Time:
- 2024-01-11 17:11:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1658551 | Amylyx Pharmaceuticals Inc. | AMLX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1235598 | M James Frates | C/O Amylyx Pharmaceuticals, Inc. 43 Thorndike Street Cambridge MA 02141 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-01-09 | 2,716 | $16.33 | 112,035 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 11,072 | Indirect | By Trust |
Footnotes
- Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.18 to $16.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.